Nervous System Diseases

Wounds and Injuries

All Conditions

Spinal Cord Compression

Spinal Cord Diseases

Central Nervous System Diseases

Spinal Cord Injuries

Antineoplastic Agents

All Drugs and Chemicals

Paclitaxel

Albumin-Bound Paclitaxel

Tubulin Modulators

Antimitotic Agents

* 10 fractions of 3Gy radiation therapy will be delivered.
* A total of 4 chemoradiation blocks should be delivered ideally in consecutive days
* On day 1 of the chemoradiation block, nab-paclitaxel is delivered in the morning followed by radiotherapy the latest possible and ideally at least 6 hours later (no earlier than 4 hours after the start of nab-paclitaxel)
* On day 2, radiotherapy is delivered in the morning, ideally within 24 hours from the start of nab-Paclitaxel infusion the previous day
* There will be 2 radiation fractions that won't be part of any chemoradiation block and can be placed anywhere before, after, or between blocks

Radiation therapy

* Dose 15 mg/m\^2
* Should be administered by IV over 30 minutes

nab-Paclitaxel

Hiram A Gay, M.D.

The purpose of this research study is to look at a combination treatment of radiation therapy and a drug called Abraxane to treat epidural spinal cord compression.

Pulsed Abraxane and Radiotherapy for Improving and Maintaining Ambulation After Cancer-Related Cord Compression

Novel Approach of Pulsed Abraxane and Radiotherapy for Improving and Maintaining Ambulation After Cancer-Related Cord Compression

-Ambulatory status is categorized as paraplegic, not ambulatory, ambulatory with aid (for example, with assistive device like walker or crutches), and ambulatory without aid.

-Strength assessment is categorized as follows: 0/5=no contraction (worst); 1/5=muscle flicker, but no movement; 2/5=movement possible, but not against gravity (test the joint in its horizontal plane); 3/5=movement possible against gravity, but not against resistance by the examiner; 4/5=movement possible against some resistance by the examiner; 5/5=normal strength (best)

-Pain is measured on a scale between 0-10. 0=no pain (best) and 10=the greatest pain (worst)

Celgene

Washington University School of Medicine

Nab-Paclitaxel and Radiation Therapy

Age, Continuous

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

United States

Region of Enrollment

Hiram A. Gay, M.D.

Paraplegic

Not ambulatory

Ambulatory with aid

Ambulatory without aid

One participant was not evaluable for this outcome measure because the ambulatory status was not completed for the participant.

Ambulatory Status

One participant was not evaluable for this outcome measure because the ambulatory status was not completed for the participant. One participant was not evaluable for this outcome measure because the participant died prior to the 3 month follow-up.

Both participants expired prior to the 6 month follow-up.

Both participants expired prior to the 9 month follow-up.

Both participants expired prior to the 12 month follow-up.

0=no contraction

1=muscle flicker, but no movement

2=movement possible, but not against gravity (test the joint in its horizontal plane)

3=movement possible against gravity, but not against resistance by the examiner

4=movement possible against some resistance by the examiner

5=normal strength

One participant was not evaluable for this outcome measure because the strength of lower extremities was not completed for the participant.

Strength of Lower Extremities

One participant was not evaluable for this outcome measure because the pain scale was not completed for the participant.

Pain in the Irradiated Area" Measured on a Scale

One participant was not evaluable for this outcome measure because the pain status was not completed for the participant. One participant was not evaluable for this outcome measure because the participant died prior to the 3 month follow-up.

Spots Global Cancer Trial Database for Pulsed Abraxane and Radiotherapy for Improving and Maintaining Ambulation After Cancer-Related Cord Compression

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial